The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge ...

Results from a new study suggest a combination of the diabetes drug Ozempic and an innovative new intestinal procedure could ...

Burke is one of a growing number of adults who suspect they might have undiagnosed ADHD. About 25% of adults think they have ...

Drugmakers and insurers are exploring different payment schemes for expensive, potentially curative treatments, particularly ones tied to patient response.

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

Pfizer has announced the approval of HYMPAVZI by the US Food and Drug Administration (FDA) for patients with haemophilia A ...

The FDA granted the approval of Hympavzi to Pfizer Inc.

Challenges in Existing Medical Summarization Tools For every claim, claims handlers spend an average of 12.5 hours reviewing complex medical data from various sources, while manag ...

A summary of recent health news includes HIV transmission via organ transplants in Brazil, a reconsideration of Eli Lilly's ...

The US Food and Drug Administration (FDA) on Friday approved US pharma giant Pfizer’s Hympavzi (marstacimab-hncq) for routine ...

Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII ...